Clinical Trial Update: Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase II study of combined temozolomide and SGT-53 for recurrent glioblastoma has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• SGT-53
• Temozolomide (Temozolomide)

Snippet

Sponsor: SynerGene Therapeutics, Inc. | Conditions: RECURRENT GLIOBLASTOMA | Phase 2 | Status: TERMINATED | Results posted: 2021-03-03